Enhancing the bioavailability of encapsulated hydrophobic nutraceuticals: Insights from in vitro, in vivo, and clinical studies

Abuhassira-Cohen, Yarden

doi:10.1016/j.cofs.2022.100832

Cited by 9 publications

(4 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of nutraceuticals in plant‐based foods does not always mean they will be able to exhibit their beneficial health effects. For instance, they may chemically degrade during food processing, storage, or preparation, or they may have a low bioavailability after consumption (Abuhassira‐Cohen & Livney, 2022; Manocha et al., 2022). Moreover, many plant‐based nutraceutical ingredients are often difficult to incorporate into food or beverage matrices because of their extremely low water solubility (Yao et al., 2015).…”

Section: Factors To Consider When Assessing the Nutritional Quality O...mentioning

confidence: 99%

Ultraprocessed plant‐based foods: Designing the next generation of healthy and sustainable alternatives to animal‐based foods

McClements

2023

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

Numerous examples of next‐generation plant‐based foods, such as meat, seafood, egg, and dairy analogs, are commercially available. These products are usually designed to have physicochemical properties, sensory attributes, and functional behaviors that match those of the animal‐sourced products they are designed to replace. However, there has been concern about the potential negative impacts of these foods on human nutrition and health. In particular, many of these products have been criticized for being ultraprocessed foods that contain numerous ingredients and are manufactured using harsh processing operations. In this article, the concept of ultraprocessed foods is introduced and its relevance to describe the properties of next‐generation plant‐based foods is discussed. Most commercial plant‐based meat, seafood, egg, and dairy analogs currently available do fall into this category, and so can be classified as ultraprocessed plant‐based (UPB) foods. The nutrient content, digestibility, bioavailability, and gut microbiome effects of UPB foods are compared to those of animal‐based foods, and the potential consequences of any differences on human health are discussed. Some commercial UPB foods would not be considered healthy based on their nutrient profiles, especially those plant‐based cheeses that contain low levels of protein and high levels of fat, starch, and salt. However, it is argued that UPB foods can be designed to have good nutritional profiles and beneficial health effects. Finally, areas where further research are still needed to create a more healthy and sustainable food supply are discussed.

show abstract

Section: Factors To Consider When Assessing the Nutritional Quality O...mentioning

confidence: 99%

Ultraprocessed plant‐based foods: Designing the next generation of healthy and sustainable alternatives to animal‐based foods

McClements

2023

Comp Rev Food Sci Food Safe

View full text Add to dashboard Cite

show abstract

“…Most of these compounds are very sensitive and unstable under specific conditions (light, heat and oxygen, among others), as well as during processing and storage [ 67 ]. Accordingly, the direct integration of food- and pharmaceutical-grade bioactive compounds and ingredients to produce functional foods, medical foods and excipient foods can be a challenge for the industry [ 68 , 69 , 70 ]. This challenge increases with the highly lipophilic properties and low and/or variable bioaccessibility and bioavailability of the bioactive compounds intended to be used in products for oral ingestion [ 71 , 72 , 73 ].…”

Section: Encapsulation Technology As An Ally In the Treatment Of Aplmentioning

confidence: 99%

Pharmaceutical/Clinical Strategies in the Treatment of Acute Promyelocytic Leukemia: All-Trans Retinoic Acid Encapsulation by Spray-Drying Technology as an Innovative Approach–Comprehensive Overview

2023

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is phenotypically characterized by the accumulation of dysplastic promyelocytes, resulting from a cytogenetic condition due to the balanced chromosomal translocation t(15;17)(q22;q21). Current first-line treatment of APL includes all-trans retinoic acid (all-trans RA), with or without arsenic trioxide, combined with chemotherapy, and a chemotherapy-free approach wherein arsenic trioxide is used alone or in combination with all-trans RA. The usage of all-trans RA revolutionized the treatment of APL, with survival rates of 80 to 90% being achieved. The mechanism of action of all-trans RA is based on regulation of gene transcription, promoting the differentiation of leukemic promyelocytes. Encapsulation technology has been explored as an innovative strategy to overcome the major drawbacks related to the all-trans RA oral administration in the APL treatment. The most recently published works on this subject highlight the development and optimization of carrier-based delivery systems based in microparticle formulations obtained by spray-drying to be used in the treatment of APL. The ultimate goal is to obtain a controlled delivery system for RA oral administration capable of providing a slow release of this bioactive compound in the intestinal lumen.

show abstract

“…The bioavailability indicator is very informative, but the procedure for determining it involves expensive in vitro [20,21] and in vivo testing, as well as clinical studies [22]. This indicator is determined based on the analysis of final and intermediate products of metabolism [23]. As a result, a number of objective consequences inevitably arise:…”

Section: Introductionmentioning

confidence: 99%

“…• bioavailability analysis is carried out post factum, which means the need to obtain a set of preliminary and basic preclinical and clinical studies [24]. Moreover, the product itself must have already been produced in some quantity and consumed by laboratory animals and focus-group patients [13,23]; • the bioavailability indicator is discrete, which is inextricably linked with the previous consequence and is characterized by a strict link to the composition and form factor of the product without the possibility of considering the dynamics of mass fractions for one or another component in the composition; • high resource consumption because preliminary and basic clinical studies are quite expensive and time-consuming and may last for up to a year or more [25,26]; • not applicable to ENPs due to the need for a dynamic design approach. This is due to the fact that the core of any design algorithm is combinatorics [27,28].…”

Section: Introductionmentioning

confidence: 99%

Development of an approach to predicting the bioavailability of enteral nutrition products

Kondratenko,

Agarkova

2024

Teor. prakt. pererab. mâsa (Print)

View full text Add to dashboard Cite

One of the key factors while developing nutritional supplements is their bioavailability. To determine it, expensive and timeconsuming clinical studies of developed products are necessary. Using in silico methods may speed up and reduce the costs of such clinical studies. The purpose of this study is to develop an approach to predicting the integral bioavailability of enteral nutrition products (ENPs) based on a comprehensive analysis of the matrices of components and indicators. The includes a comprehensive empirical study based on a comparative statistical analysis of the matrix of studied ENPs components. Available information on the composition and indicators of 52 commercial ENPs was used as a research object. This information was compiled into a matrix of components and indicators, marked according to the intended purposes of the products. The set of products included in the matrix was divided into 2 subsets: ENPs corresponding to a given intended purpose and other ENPs. This made it possible to separate statistically significant components and indicators that define the intended purpose of the product with a given threshold of the maximum error probability for inequality of mean values. Using Harrington’s desirability principle in relation to the identified components and indicators made it possible to obtain an integral estimate of desirability for a given intended purpose. A vector characterizing the distance from the integral estimate to the ideal value was introduced as equivalent predicted bioavailability. The upper limit of the optimal range is 0.37, the upper limit of the acceptable range is 0.63. The predicted bioavailability vector scale is the inverse of the integral desirability scale. In contrast to Harrington scaling, the lower the predicted bioavailability value, the more preferable it is. Analysis of the introduced indicator allowed us to establish significant variability in commercial ENPs with respect to predicted bioavailability for diabetes mellitus and thermal injury. Based on the proposed predicted bioavailability vector, a principle has been developed for the evolutionary development of a statistical approach to predicting bioavailability when designing ENPs. This principle is a universal addition to the principle of food combinatorics while developing meat, dairy and plant-based ENPs.

show abstract

Enhancing the bioavailability of encapsulated hydrophobic nutraceuticals: Insights from in vitro, in vivo, and clinical studies

Cited by 9 publications

References 66 publications

Ultraprocessed plant‐based foods: Designing the next generation of healthy and sustainable alternatives to animal‐based foods

Ultraprocessed plant‐based foods: Designing the next generation of healthy and sustainable alternatives to animal‐based foods

Pharmaceutical/Clinical Strategies in the Treatment of Acute Promyelocytic Leukemia: All-Trans Retinoic Acid Encapsulation by Spray-Drying Technology as an Innovative Approach–Comprehensive Overview

Development of an approach to predicting the bioavailability of enteral nutrition products

Contact Info

Product

Resources

About